World News

Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line...

Ogkologos - 7 Ιουνίου, 2023

Reunión anual de la American Society of Clinical Oncology de 2023:...

Ogkologos - 6 Ιουνίου, 2023

ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After...

Ogkologos - 6 Ιουνίου, 2023

FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated...

Ogkologos - 6 Ιουνίου, 2023

ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and...

Ogkologos - 5 Ιουνίου, 2023

Can Cancer Prevention Be Better Integrated into Primary Care?

Ogkologos - 5 Ιουνίου, 2023

Reunión anual de la American Society of Clinical Oncology de 2023:...

Ogkologos - 5 Ιουνίου, 2023

Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,...

Ogkologos - 5 Ιουνίου, 2023

Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with...

Ogkologos - 5 Ιουνίου, 2023

ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung...

Ogkologos - 4 Ιουνίου, 2023

1...127128129...432 Σελίδα 128 από 432

MOST POPULAR

FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with...

20 Νοεμβρίου, 2025

ESMO Targeted Anticancer Therapies Congress 2023

24 Φεβρουαρίου, 2023

Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in...

4 Ιουλίου, 2024

Efficacy and Safety of Trastuzumab Deruxtecan in Exploratory Cohorts of Patients...

23 Νοεμβρίου, 2022

Φόρτωση περισσοτέρων

Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line...

Reunión anual de la American Society of Clinical Oncology de 2023:...

ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After...

FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated...

ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and...

Can Cancer Prevention Be Better Integrated into Primary Care?

Reunión anual de la American Society of Clinical Oncology de 2023:...

Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,...

Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with...

ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung...

MOST POPULAR

FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with...

ESMO Targeted Anticancer Therapies Congress 2023

Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in...

Efficacy and Safety of Trastuzumab Deruxtecan in Exploratory Cohorts of Patients...

HOT NEWS

Έγκριση νέας επικουρικής θεραπείας για τον θετικά πρώιμο καρκίνο του μαστού

Treatment in Breast Cancer Patients Over 70 May Be Safely Reduced

EMA Recommends Granting a Marketing Authorisation for Catumaxomab

FDA Approves Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma with a...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ